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ABSTRACT
Background: Longstanding and diverse body of  evidence 
supports the view that sex steroids play a role in the 
development of  prostate cancer. Epidemiological and 
demographic studies in humans as well as animal 
experiments have sought to determine the independent 
effect on risk as well as the interrelationship between these 
hormones.  In this study, we investigated the variations in 
testosterone and oestradiol levels among prostate cancer 
patients attending UPTH clinics with the objective of  
determining the role played by sex hormone variations in 
the development of  cancer of  prostate in patients attending 
the University of  Port Harcourt Teaching, Port Harcourt.
Methods: Newly diagnosed patients with cancer of  the 
prostate attending the Urology clinic of  University of  Port 
Harcourt Teaching, Port Harcourt from December 2011 to 
April 2012 were recruited for the study.  Their Prostate 
Specific Antigen (PSA) testosterone and oestrogens levels 
were measured using Elisa Kits.  Correlation between 
individual hormone levels in control subjects were assessed 
by Spearman correlation coefficients (R). Student t-test 
was used to assess if  there was any significant difference 
between the patients and controls in the level of  these 
hormones. We computed the ratio of  oestradiol to 
testosterone and compared case patients with control 
subjects by use of  t-test at 95% confidence interval. Test 
cases were also divided into two groups by age to study 
variations across subgroups.
Results: 105 patients recently diagnosed with prostate 
cancer and 40 normal subjects were analyzed. We observed 
a negative correlation between testosterone and oestradiol 
(r = -0.66). Testosterone and oestradiol levels in prostate 
cancer patients were also significantly different from that 
of  controls. Mean testosterone level in control was 3.2 
ng/ml while that of  the patients was 4.0 ng /ml.  Mean 
oestradiol level in controls was 32.8 pg/ml while that of  the 
patients was 21.2pg/ml (p < 0.05 in both cases). The ratio 
of  oestradiol to testosterone was also significantly altered 
in prostate cancer patients (p < 0.05). The mean levels of  
hormones and hormone ratios across the two sub-age 
groups were not substantially different in patients with 
prostate cancer (p > 0.05).
Conclusion: This study indicates that increased levels of  
testosterone in circulation are associated with risk of  
prostate cancer. This risk is further associated with low 
levels of  circulating oestradiol. The relative levels or ratio 
INTRODUCTION
Prostate cancer was the second most frequently diagnosed 
cancer and the sixth leading cause of  cancer related death 
1  in males worldwide as at 2011 . In Nigeria, 2% of  men 
develop cancer of  the prostate with a prevalence of  127 per 
2100,000 . It has long been documented that sex steroids, 
particularly androgens play a role in the pathogenesis of  
3prostate cancer . Data from animal experiments and from 
epidemiological and endocrinological studies in humans 
supports the evidence that the individual hormones which 
control normal growth of  target organs can also create the 
proper conditions for endoplasmic transformation. 
Androgens are essential for normal growth and 
maintenance of  the prostate gland; however it has also been 
proven from studies to stimulate the proliferation of  human 
prostate cancer cells in vitro and can indeed cause prostate 
4, 5cancer in rodents when given in large quantities .
Androgen deprivation frequently causes prostate cancer to 
regress and is a common approach in prostate cancer 
therapy. Additionally it is known that eunuchs rarely 
6develop prostate cancer  (Huggins and Hodges, 1941). On 
the other hand, estrogen therapy has a palliative effect in 
advanced prostate cancer and a reduced risk of  prostate 
cancer has been associated with certain hyper-estrogenic 
3states .  Gann and his co-workers in their study particularly 
observed an association between testosterone and prostate 
cancer.  The association with estrogen was though weaker. 
These observations add credibility to the well-known fact 
that extreme variations in sex hormone levels constitute a 
risk and indeed play a role in the etiology of  prostate 
7  cancer . As far back as 1948, there was already evidence 
suggesting that exogenous estrogen causes extreme 
degeneration in the peripheral zone of  the prostate where 
8most cancers arise but very little in the central zone .
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of  these hormones are very important in the development 
of  prostate cancer. Age of  the patient appear not to be 
strongly related with these changes after the cancerous 
state has set in.
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Studies on the role of  sex steroids in prostate cancer have been 
done in the Niger delta region of  Nigeria seem to be 
uncommon. We have therefore assessed the androgen and 
estrogen hormone levels in prostate cancer patients attending 
the Urology clinic of  the University of  Port Harcourt 
Teaching Hospital. Our focus was on testosterone and 
estrogen, the major contributors of  androgenic and 
estrogenic activities in the body respectively.
METHODS
Study Design and Population: This was a cross sectional 
prospective study comparative study. Samples were collected 
from patients from the surgical outpatient and urology clinics 
of  the University of  Port Harcourt Teaching Hospital who 
came to the Hormone Laboratory of  the Department of  
Chemical Pathology to do their PSA tests from December 
2011 and April 2012. 
Inclusion criteria for the subjects were a recent diagnosis of  
histologically confirmed prostate cancer irrespective of  the 
stage. Patients who had already initiated therapy or who have 
had an orchidectomy and or prostatectomy were excluded 
from the study. 
Control subjects were selected from cases that had come to 
the Hormone Lab for routine PSA screening. Those selected 
as controls were those who had their PSA levels falling within 
the normal range (0-4 ng/ml), and who had no previous 
history of  prostatectomy and were not on any known drugs 
for prostate disease.  
Sample Collection: Blood samples from patients that met 
the criteria for the study were collected into plain sample 
bottles by venipuncture at the phlebotomy unit of  Chemical 
Pathology Department. Serum obtained from the samples 
after centrifugation at 2,000g was stored in a frozen state for 
not more than 2 weeks before analysis.
Laboratory Assays: Previously unthawed serum samples for 
case patients and controls were analyzed at the Hormone Lab 
of  Chemical Pathology Department of  the University of  Port 
Harcourt Teaching, Port Harcourt.  Samples were run in 
batches and in duplicates. PSA, testosterone and estradiol 
were measured by use of  Enzyme Linked Immunoassay kits 
obtained from BioCheck (Vintage Park Dr., Foster City, CA).
Data Analysis: Data were analyzed for each group of  sample 
to obtain the mean, standard deviation and coefficient of  
variation for control and test subjects for the different 
parameters. The student t-test was used to determine 
significance of  difference in mean of  the two groups at 95% 
confidence interval. Correlations between hormone levels 
were evaluated using the control data only by calculation of  
Spearman correlation coefficient. 
We assessed for trends or variation across sub-groups by 
dividing the test group into two sub-groups by age. We also 
computed the ratio of  estradiol to testosterone, a ratio that has 
been construed as an index of  hormone balance or 
metabolism and compared the test patients with control 
subjects to see if  there was any significant difference.
Ethical Clearance: Ethical approval was sought from the 
University of  Port Harcourt Teaching Hospital, ethics and 
research committee and all patients gave informed consent to 
participate in the study.
RESULTS
One hundred and five patients (105) patients were selected for 
the study and forty (40) control subjects were tested. As 
shown in table 1, the mean age of  the study group was 71.8 
years while it is 54.2 years for the controls (p <0.5).
The mean PSA level was 60.7 ng/ml for the study group and 
1.3ng/ml for the controls (p<0.05). The mean testosterone 
level of  the patients was 4.0ng/ml. This was significantly 
different from that of  the control subjects (3.2ng/ml), p<0.05. 
The mean values of  oestradiol in patient group was also 
significantly different from that of  the control group; 
21.2pg/ml and 32.8pg/ml respectively (P<0.05). The 
oestradiol to testosterone ratio (E2/T) in patient group was 
5.3, while ratio was 10.7 in the control group. This was 
significantly different (p<0.05). The mean values for the 
testosterone and oestradiol as well as their ratios were also 
shown in table 1. The P values and results of  Students''t' test at 
95% confidence interval were recorded as well. 
Table 2 shows the mean values of  the selected parameters for 
the test group subdivided into two groups by age. The mean 
levels of  hormones and hormone ratios are not substantially 
different in the 2 subgroups of  patients already diagnosed 
with prostate cancer. There was no significant difference in 
the parameters in the case patients below and above the ages 
of  70 years.
There was a significant negative correlation for the 
association between estradiol and testosterone among 
control subjects.  The correlation Coefficient(R) was -0.66 
with P>0.05 as shown in Table 3.
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Table1. Mean levels of selected parameters for prostate 




The mean age of  our prostate cancer patients was 71.8 years. 
1, 9This is in keeping with other studies in Nigeria and USA. . 
This further confirms the known fact that old age is one of  the 
major known risk factors for development of  prostate cancer.
In this study, significantly higher levels of  testosterone-within 
the normal endogenous range, were observed in prostate 
cancer patients implicating a role of  testosterone in prostatic 
cancer. Testosterone levels were higher in case patients as 
compared with normal subjects. On the other hand, low levels 
of  estradiol were associated with prostate cancer patients. 
These findings are in line with previous studies which 
suggests that the primary mechanism involved in prostate 
cancer pathogenesis might probably depend more on 
modification of  the factors which affect secretion and 
metabolism of  the responsible hormone rather than on 
4,10-13exposure to classical exogenous initiators . Testosterone is 
converted to dihydrotestosterone, which in turn supports the 
growth of  the prostate. This higher level of  testosterone thus 
translates to a greater possibility of  proliferation of  prostatic 
cells. It is therefore not surprising that we observed higher 
levels of  testosterone for the prostate cancer patients when 
compared with normal controls.
  
We observed a negative correlation between testosterone and 
14estradiol. This is at variance with the findings of  Gann et al 
3  (1996), but does agree with other findings . As was stated 
earlier, a reduced risk of  cancer is associated with certain 
hyper-estrogenic states and estrogen therapy has a palliative 
3, 6effect in advanced states . It does appear that the metabolic 
balance between estrogen and testosterone is altered in the 
cancerous state indicating that the ratio of  these hormones 
rather than their absolute values may be more important in 
the pathogenesis of  prostate cancer. We observed a significant 
difference in the ratios of  estrogen to testosterone in prostate 
cancer patients (p<0.05).
We divided the case study patients into 2 groups by age 60-70 
years and 71 years and above, in order to see if  age had any 
effect on these outcomes. From our results (Table2), there 
was no significant difference in the mean level of  estrogen and 
testosterone in the different age groups. There was a slight 
difference in the mean of  the ratio of  estrogen to testosterone 
but this was not significant suggesting again that the ratio of  
these hormones rather than their absolute values are 
implicated in prostate cancer etiology. Though the risk of  
prostate cancers and benign hypertrophy increases with age, 
it does appear that after the cancerous state has set in, these 
ratios rather than other factors play a greater role in creating 
the favorable environment for these cancerous cells to 
.5proliferate .
The result of  this study does support the theory that long term 
exposure to modifications in the levels of  endogenous 
testosterone and estradiol is implicated in prostate cancer 
development. In this study we did not include sex hormone 
binding globulin (SHBG). The outcome of  this study may 
have been different if  this had been measured, as there is the 
hypothesis that only the bioavailable hormone and not 
protein bound component is free to enter into cells to initiate 
15action . This is one limitation of  this study. Forty four 
percent of  all circulating testosterone is bound to SHBG, 2% 
is free and the rest is loosely bound to albumin and can enter 
cells to mediate an effect. Similar distribution applies to 
estrogen though it has a weaker binding affinity for SHBG. It 
follows therefore that increases or decreases in SHBG levels 
would affect bioavailability of  both testosterone and 
16estrogen . 
The Levels of  testosterone, estrogen and SHBG could have 
overlapping or distinct set of  effects on prostate cancer. 
Investigation of  what independent or confounding effect on 
risk hormones may have and modification of  these levels with 
the goal of  developing models for prostate cancer prevention 
or therapy should guide further research. 
CONCLUSION
This study indicates that increased levels of  testosterone in 
circulation are associated with the risk of  developing prostate 
cancer. This risk is further associated with low levels of  
circulating oestradiol. The relative levels or ratio of  these 
hormones are very important in the development of  prostate 
cancer. Age of  the patient appear not to be strongly related 
with these changes after the cancerous state has set in.
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